KEGG DRUG

Search results

No.	Drug (Description in trials)	DrugBank	KEGG DRUG	KEGG GENES	KEGG PATHWAY	Disease ID
1	Visilizumab	[1] Visilizumab	[1] D06314 (Name: Visilizumab)	[3] CD3D, CD3E, CD3G 💬	[11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬	[2] 96, 97
2	Visilizumab (HuM291	[1] Visilizumab	[1] D06314 (Name: Visilizumab)	[3] CD3D, CD3E, CD3G 💬	[11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬	[1] 97
3	Visilizumab (Nuvion)	[1] Visilizumab	[1] D06314 (Name: Visilizumab)	[3] CD3D, CD3E, CD3G 💬	[11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬	[1] 97
4	Visilizumab (Nuvion®	[1] Visilizumab	[1] D06314 (Name: Visilizumab)	[3] CD3D, CD3E, CD3G 💬	[11] Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬	[1] 97